ApconiX Welcomes Dr Laurence Bishop ApconiX is delighted to welcome Dr Laurence Bishop to the team as our Head of Business Development. Laurence is an experienced DMPK and toxicological scientist with 20 years’ experience of nonclinical drug development. Specialising in business development for the past 13 years, we are [...]
Dr Guy Healing Appointed Honorary Professor ApconiX is pleased to announce that Dr Guy Healing has been appointed to an Honorary Professorship in the School of Pharmacy at the University of East Anglia (UEA), Norwich, UK. Guy first became involved with the UEA when he worked for AstraZeneca. One [...]
Sophion’s Ion Channel Modulation Symposium Dr Michael Morton will be attending Sophion’s Ion Channel Modulation Symposium, on the 19th to 20th of June 2019, at Clare College in Cambridge, UK. Sophion was founded almost twenty years ago by a group of passionate electrophysiologists and offers the some of the [...]
ApconiX Joins the MDC’s Virtual R&D platform ApconiX has joined the Medicines Discovery Catapult’s Virtual R&D platform. This is a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management. ApconiX specialises in ion [...]
ApconiX Attends British Toxicology Society Congress - "Celebrating 40 years of the BTS". British Toxicology Society (BTS) and the UK Environmental Mutagen Society Annual Congress “Celebrating 40 years of the BTS" will be held at Robinson College, University of Cambridge between 15th -17th of April. Professor Ruth Roberts, Dr Richard [...]
Successful DMDG Symposium at Alderley Park The DMDG Symposium at Alderley Park was a great success. Organised by the teams from Sygnature, Alderley Park and ApconiX, over 120 delegates from around the country joined the symposium Dx Toxicology: Strategies for Success in Discovery and Development, focusing on asking the [...]
ApconiX Celebrates Opening Swedish Office Dr Michael Morton, Professor Ruth Roberts and Dr Richard Knight flew to Sweden to celebrate the opening of ApconiX AB in Gothenburg by sharing coffee and cake (fika) with our fellow tenants in the BioVentureHub. Experienced toxicologists Drs Steffen Ernst and Björn Dahl, who [...]
Symposium – Dx Toxicology: Strategies for Success in Discovery and Development Attrition due to safety/toxicity remains a challenge in drug discovery and development. Strategies to improve success focus on asking the right questions at the right time around Target, Chemistry and Patient with an emphasis on translation of data [...]
ApconiX Welcomes Dr Steffen Ernst ApconiX is delighted to welcome Dr Steffen Ernst to our team, as the company begins its international expansion with the formation of its Swedish subsidiary, ApconiX AB. Steffen has worked in preclinical and clinical safety for over 20 years with Hoechst-Schering, Boehringer-Ingelheim, AstraZeneca, Pfizer [...]
ApconiX Welcomes Steve Snyder ApconiX is delighted to welcome Steve Snyder to the team. Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical [...]
